Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome

Qianmei CAO; Zhechuan MEI

doi:10.3969/j.issn.1001-5256.2021.10.038

Volume 37 Issue 10

Oct. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(10): 2439-2443

PDF( 1903 KB)

Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome

DOI: 10.3969/j.issn.1001-5256.2021.10.038

Qianmei CAO,
Zhechuan MEI^,

Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

Received Date: 2021-03-01
Accepted Date: 2021-03-15
Published Date: 2021-10-20

Abstract

Abstract

Hepatorenal syndrome (HRS) is a serious complication of end-stage liver disease often observed in advanced liver cirrhosis patients with circulatory dysfunction and tends to have poor prognosis. At present, terlipressin combined with albumin is the preferred drug treatment regimen for HRS. Many studies have been conducted on the predictive factors for the therapeutic effect of terlipressin combined with albumin, but there lacks a comprehensive report of these studies. This article reviews the latest research advances in this disease and its treatment from the pathogenesis of HRS and the mechanism of action of drugs, as well as the research advances in the predictive factors for the therapeutic effect of terlipressin combined with albumin in terms of baseline data, changes after treatment, and treatment regimens. It is pointed out that early identification of factors that can help predict treatment response has important clinical significance.
- Liver Cirrhosis,
- Hepatorenal Syndrome,
- Treatment Outcome

FullText(HTML)

References(50)

References

[1]	ANGELI P, GINÈS P, WONG F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol, 2015, 62(4): 968-974. DOI: 10.1016/j.jhep.2014.12.029.
[2]	RICE JP, SKAGEN C, SAID A. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin[J]. Transplantation, 2011, 91(10): 1141-1147. DOI: 10.1097/TP.0b013e31821690bf.
[3]	SALERNO F, CAZZANIGA M, MERLI M, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice[J]. J Hepatol, 2011, 55(6): 1241-1248. DOI: 10.1016/j.jhep.2011.03.012.
[4]	SALERNO F, GERBES A, GINÀS P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis[J]. Gut, 2007, 56(9): 1310-1318. DOI: 10.1136/gut.2006.107789.
[5]	SALERNO F, NAVICKIS RJ, WILKES MM. Albumin treatment regimen for type 1 hepatorenal syndrome: A dose-response meta-analysis[J]. BMC Gastroenterol, 2015, 15: 167. DOI: 10.1186/s12876-015-0389-9.
[6]	WONG F. Recent advances in our understanding of hepatorenal syndrome[J]. Nat Rev Gastroenterol Hepatol, 2012, 9(7): 382-391. DOI: 10.1038/nrgastro.2012.96.
[7]	FERNANDEZ-SEARA J, PRIETO J, QUIROGA J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure[J]. Gastroenterology, 1989, 97(5): 1304-1312. DOI: 10.1016/0016-5085(89)91704-6.
[8]	SOLÀ E, GINÈS P. Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives[J]. J Hepatol, 2010, 53(6): 1135-1145. DOI: 10.1016/j.jhep.2010.08.001.
[9]	CHUANG CL, CHANG CC, HSU SJ, et al. Endotoxemia-enhanced renal vascular reactivity to endothelin-1 in cirrhotic rats[J]. Am J Physiol Gastrointest Liver Physiol, 2018, 315(5): g752-g761. DOI: 10.1152/ajpgi.00302.2017.
[10]	KRAG A, GLUUD LL. Cross-talk between the liver, heart and kidney - another piece in the puzzle[J]. J Gastrointestin Liver Dis, 2014, 23(2): 119-121. DOI: 10.15403/jgld.2014.1121.ak1.
[11]	KRAG A, BENDTSEN F, HENRIKSEN JH, et al. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites[J]. Gut, 2010, 59(1): 105-110. DOI: 10.1136/gut.2009.180570.
[12]	VELEZ J, THERAPONDOS G, JUNCOS LA. Reappraising the spectrum of AKI and hepatorenal syndrome in patients with cirrhosis[J]. Nat Rev Nephrol, 2020, 16(3): 137-155. DOI: 10.1038/s41581-019-0218-4.
[13]	ACEVEDO J, FERNÁNDEZ J, PRADO V, et al. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death[J]. Hepatology, 2013, 58(5): 1757-1765. DOI: 10.1002/hep.26535.
[14]	THABUT D, MASSARD J, GANGLOFF A, et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure[J]. Hepatology, 2007, 46(6): 1872-1882. DOI: 10.1002/hep.21920.
[15]	HAMPEL H, BYNUM GD, ZAMORA E, et al. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis[J]. Am J Gastroenterol, 2001, 96(7): 2206-2210. DOI: 10.1111/j.1572-0241.2001.03958.x.
[16]	LANG F, TSCHERNKO E, SCHULZE E, et al. Hepatorenal reflex regulating kidney function[J]. Hepatology, 1991, 14(4 Pt 1): 590-594. DOI: 10.1016/0270-9139(91)90043-u.
[17]	SOLANKI P, CHAWLA A, GARG R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo-controlled clinical trial[J]. J Gastroenterol Hepatol, 2003, 18(2): 152-156. DOI: 10.1046/j.1440-1746.2003.02934.x.
[18]	NARAHARA Y, KANAZAWA H, TAKI Y, et al. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis[J]. J Gastroenterol Hepatol, 2009, 24(11): 1791-1797. DOI: 10.1111/j.1440-1746.2009.05873.x.
[19]	ALESSANDRIA C, OTTOBRELLI A, DEBERNARDI-VENON W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study[J]. J Hepatol, 2007, 47(4): 499-505. DOI: 10.1016/j.jhep.2007.04.010.
[20]	WONG F, PAPPAS SC, BOYER TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome[J]. Clin Gastroenterol Hepatol, 2017, 15(2): 266-272. e1. DOI: 10.1016/j.cgh.2016.07.016.
[21]	GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology, 2013, 58(5): 1836-1846. DOI: 10.1002/hep.26338.
[22]	UMGELTER A, WAGNER KS, REINDL W, et al. Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1[J]. Ann Hepatol, 2012, 11(2): 232-239.
[23]	BRINCH K, MØLLER S, BENDTSEN F, et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease[J]. J Hepatol, 2003, 39(1): 24-31. DOI: 10.1016/s0168-8278(03)00160-0.
[24]	GLUUD LL, CHRISTENSEN K, CHRISTENSEN E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome[J]. Hepatology, 2010, 51(2): 576-584. DOI: 10.1002/hep.23286.
[25]	HINZ M, WREE A, JOCHUM C, et al. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome[J]. Ann Hepatol, 2013, 12(1): 92-99.
[26]	TESTRO AG, WONGSEELASHOTE S, ANGUS PW, et al. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome[J]. J Gastroenterol Hepatol, 2008, 23(10): 1535-1540. DOI: 10.1111/j.1440-1746.2007.05176.x.
[27]	SHARMA P, KUMAR A, SHRAMA BC, et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response[J]. Am J Gastroenterol, 2008, 103(7): 1689-1697. DOI: 10.1111/j.1572-0241.2008.01828.x.
[28]	RODRÍGUEZ E, ELIA C, SOLÀ E, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis[J]. J Hepatol, 2014, 60(5): 955-961. DOI: 10.1016/j.jhep.2013.12.032.
[29]	GHOSH S, CHOUDHARY NS, SHARMA AK, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: A randomized pilot study[J]. Liver Int, 2013, 33(8): 1187-1193. DOI: 10.1111/liv.12179.
[30]	MARTÍN-LLAHÍ M, PÉPIN MN, GUEVARA M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: A randomized study[J]. Gastroenterology, 2008, 134(5): 1352-1359. DOI: 10.1053/j.gastro.2008.02.024.
[31]	SANYAL AJ, BOYER T, GARCIA-TSAO G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gastroenterology, 2008, 134(5): 1360-1368. DOI: 10.1053/j.gastro.2008.02.014.
[32]	SARWAR S, KHAN AA. Hepatorenal syndrome: Response to terlipressin and albumin and its determinants[J]. Pak J Med Sci, 2016, 32(2): 274-278. DOI: 10.12669/pjms.322.9315.
[33]	BOYER TD, SANYAL AJ, GARCIA-TSAO G, et al. Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics[J]. J Hepatol, 2011, 55(2): 315-321. DOI: 10.1016/j.jhep.2010.11.020.
[34]	NAZAR A, PEREIRA GH, GUEVARA M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome[J]. Hepatology, 2010, 51(1): 219-226. DOI: 10.1002/hep.23283.
[35]	ABDEL-RAZIK A, MOUSA N, ABDELSALAM M, et al. Endothelin-1/nitric oxide ratio as a predictive factor of response to therapy with terlipressin and albumin in patients with type-1 hepatorenal syndrome[J]. Front Pharmacol, 2020, 11: 9. DOI: 10.3389/fphar.2020.00009.
[36]	HEIDEMANN J, BARTELS C, BERSSENBRVGGE C, et al. Hepatorenal syndrome: Outcome of response to therapy and predictors of survival[J]. Gastroenterol Res Pract, 2015, 2015: 457613. DOI: 10.1155/2015/457613.
[37]	ALLEGRETTI A, PARADA X, ENDRES P, et al. Urinary NGAL as a diagnostic and prognostic marker for acute kidney injury in cirrhosis: A prospective study[J]. Clin Transl Gastroenterol, 2021, 12(5): e00359. DOI: 10.14309/ctg.0000000000000359.
[38]	APPENRODT B, ZIELINSKI J, BRENSING KA, et al. Degree of hepatic dysfunction and improvement of renal function predict survival in patients with HRS type I: A retrospective analysis[J]. Eur J Gastroenterol Hepatol, 2009, 21(12): 1428-1432. DOI: 10.1097/MEG.0b013e32832ec16a.
[39]	SINGH V, GHOSH S, SINGH B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: A randomized study[J]. J Hepatol, 2012, 56(6): 1293-1298. DOI: 10.1016/j.jhep.2012.01.012.
[40]	CAVALLIN M, PIANO S, ROMANO A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study[J]. Hepatology, 2016, 63(3): 983-992. DOI: 10.1002/hep.28396.
[41]	von KALCKREUTH V, GLOWA F, GEIBLER M, et al. Terlipressin in 30 patients with hepatorenal syndrome: Results of a retrospective study[J]. Z Gastroenterol, 2009, 47(1): 21-26. DOI: 10.1055/s-0028-1109084.
[42]	PIANO S, MORANDO F, FASOLATO S, et al. Continuous recurrence of type 1 hepatorenal syndrome and long-term treatment with terlipressin and albumin: A new exception to MELD score in the allocation system to liver transplantation?[J]. J Hepatol, 2011, 55(2): 491-496. DOI: 10.1016/j.jhep.2011.02.002.
[43]	WONG F, PAPPAS SC, BOYER TD, et al. Terlipressin improves renal function and reverses hepatorenal syndrome in patients with systemic inflammatory response syndrome[J]. Clin Gastroenterol Hepatol, 2017, 15(2): 266-272. e1. DOI: 10.1016/j.cgh.2016.07.016.
[44]	MOREAU R, BARRIÈRE E, TAZI KA, et al. Terlipressin inhibits in vivo aortic iNOS expression induced by lipopolysaccharide in rats with biliary cirrhosis[J]. Hepatology, 2002, 36(5): 1070-1078. DOI: 10.1053/jhep.2002.36501.
[45]	MADDUKURI G, CAI CX, MUNIGALA S, et al. Targeting an early and substantial increase in mean arterial pressure is critical in the management of type 1 hepatorenal syndrome: A combined retrospective and pilot study[J]. Dig Dis Sci, 2014, 59(2): 471-481. DOI: 10.1007/s10620-013-2899-z.
[46]	VELEZ JC, NIETERT PJ. Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: A pooled analysis of clinical trials[J]. Am J Kidney Dis, 2011, 58(6): 928-938. DOI: 10.1053/j.ajkd.2011.07.017.
[47]	SCHNEIDER AG, SCHELLEMAN A, GOODWIN MD, et al. Contrast-enhanced ultrasound evaluation of the renal microcirculation response to terlipressin in hepato-renal syndrome: A preliminary report[J]. Ren Fail, 2015, 37(1): 175-179. DOI: 10.3109/0886022X.2014.977140.
[48]	MOORE K, WENDON J, FRAZER M, et al. Plasma endothelin immunoreactivity in liver disease and hepatorenal syndrome[J]. N Engl J Med, 1992, 327(25): 1774-1778. DOI: 10.1056/NEJM199212173272502.
[49]	DONG T, ARONSOHN A, GAUTHAM REDDY K, et al. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis[J]. Dig Dis Sci, 2016, 61(12): 3621-3626. DOI: 10.1007/s10620-016-4313-0.
[50]	KALAMBOKIS GN, MOUZAKI A, RODI M, et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites[J]. Clin Gastroenterol Hepatol, 2012, 10(7): 815-818. DOI: 10.1016/j.cgh.2012.02.025.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (419) PDF downloads(44)

Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome

DOI: 10.3969/j.issn.1001-5256.2021.10.038

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome

DOI: 10.3969/j.issn.1001-5256.2021.10.038

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content